Defendant
1 case as defendant.
Roche Diagnostics GmbH is a German operating subsidiary of Roche Holding AG (SIX: ROGE; OTC: RHHBY), a Swiss pharmaceutical and diagnostics group headquartered in Basel. The GmbH is based at Sandhofer Strasse 116, Mannheim, Germany, and manufactures and distributes in-vitro diagnostic reagents, instruments, and related services. Its Mannheim site traces to C.F. Boehringer & Söhne (1872) and came into Roche through the 1997 acquisition of Boehringer Mannheim. Roche does not report the GmbH separately; the Mannheim site is one of Roche's largest, with roughly 8,000–8,400 employees. Parent Roche Holding reported about 103,000 employees and CHF 63.4 billion in 2025 revenue.
Operations. The Mannheim site develops and produces in-vitro diagnostics reagents (several hundred parameters tested in blood, urine, saliva, and tissue), clinical chemistry and immunochemistry analyzer reagents, coagulation (haemostasis) monitoring systems, blood-glucose meters, test strips, insulin pumps, and point-of-care tests, plus parenteral pharmaceutical fill-finish (ampoules, lyophilisates, pre-filled syringes). It also runs a global Roche Diagnostics logistics center shipping to 150+ countries. ISO 13485-certified in-vitro diagnostic device manufacturing and distribution.
Litigation posture. Roche Diagnostics GmbH is an operating company, not an NPE. In the tracked data it appears once, as a defendant (0 plaintiff cases, 1 defendant case). It is a large, sophisticated diagnostics manufacturer defending a third-party patent suit, not a revenue-generating litigant. The single case is not in a plaintiff-friendly venue; it was filed in the Southern District of California (San Diego), Judge Irma E. Gonzalez presiding, Magistrate William V. Gallo.
Notable case. Troll Busters LLC v. Roche Diagnostics GmbH et al., No. 3:11-cv-00056 (S.D. Cal., filed Jan. 10, 2011). Plaintiff Troll Busters — a qui tam false-marking plaintiff — alleged that Roche and numerous diagnostics/biotech defendants falsely marked products under 35 U.S.C. § 292 with 22 expired PCR and molecular-biology patents (e.g., U.S. 4,683,195), including marking of LightCycler systems. Co-defendants included Life Technologies, Qiagen, Thermo Fisher, Clontech, IDT, and others; the United States intervened as defendant. The court granted motions to dismiss the first amended complaint (Aug. 31, 2011), and the case was voluntarily dismissed in October 2011. The dispute reflects Roche's position as a licensor of foundational PCR technology rather than any patent-assertion activity of its own.
False marking action under 35 U.S.C. § 292 alleging defendants marked products with twenty-two expired PCR/molecular-biology patents, including US 4,889,818, after those patents had expired. The case was closed on 09/01/2011.